This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bentoucha, A.
Right arrow Articles by Grosset, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bentoucha, A.
Right arrow Articles by Grosset, J.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, November 2001, p. 3109-3112, Vol. 45, No. 11
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.11.3109-3112.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Activities of New Macrolides and Fluoroquinolones against Mycobacterium ulcerans Infection in Mice

Abdelhalim Bentoucha, Jérôme Robert, Hervé Dega, Nacer Lounis, Vincent Jarlier, and Jacques Grosset*

Laboratoire de Bactériologie, Faculté de Médecine Pitié-Salpêtrière, Paris, France

Received 26 March 2001/Returned for modification 4 June 2001/Accepted 8 August 2001

Mice infected in the left hind footpad with 5 log10 acid-fast bacilli of Mycobacterium ulcerans were divided into an untreated control group and 17 treatment groups that received one of the following regimens for 4 weeks (all doses in milligrams per kilogram): 100 mg of azithromycin (AZM), 100 mg of clarithromycin (CLR), or 50 mg of AZM for a duration of 5 days a week (daily), three times a week, or once weekly. In addition, the following regimens were administered daily: 100 mg of telithromycin (TLM), sparfloxacin (SPX), or moxifloxacin (MOX); 200 mg of levofloxacin (LVX); 100 mg of streptomycin (STR) or amikacin (AMK); 10 mg of rifampin (RIF); and the combination of 10 mg of RIF and 100 mg of AMK (RIF+AMK). After completion of treatment, mice were observed for 30 weeks. The effectiveness of treatment regimens was assessed in terms of the delay in median time to footpad swelling in treated mice compared with that in the untreated controls. Clear-cut bactericidal activity, i.e., an observed delay in footpad swelling that exceeded the period of treatment, was observed in the STR-, AMK-, and RIF+AMK-treated mice. However, all mice treated with either AMK or STR alone had swollen footpads before the end of the 30-week observation period, suggesting regrowth of M. ulcerans. In contrast, 50% of the mice treated with the RIF+AMK combination exhibited no lesion even after 30 weeks, suggesting cure. The remaining regimens could be assigned to one of three groups: (i) no activity (50 mg of AZM, 100 mg of AZM thrice weekly, TLM, and LVX); (ii) bacteriostatic activity, i.e., a delay in footpad swelling shorter than the 4-week treatment duration (100 mg of AZM daily or once weekly, CLR thrice or once weekly, and MOX); or (iii) weak bactericidal activity (CLR daily and SPX). The RIF+AMK combination and possibly RIF+STR warrant further study for the treatment of M. ulcerans infection in humans.

* Corresponding author. Mailing address: Laboratoire de Bactériologie, Faculté de Médecine Pitié-Salpêtrière, 91 Boulevard de l'Hôpital, 75634 Paris Cedex 13, France. Phone: (33) 1 40 77 97 46. Fax: (33) 1 45 82 75 77. E-mail: jacques_grosset{at}yahoo.com.

Antimicrobial Agents and Chemotherapy, November 2001, p. 3109-3112, Vol. 45, No. 11
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.11.3109-3112.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Chauty, A., Ardant, M.-F., Adeye, A., Euverte, H., Guedenon, A., Johnson, C., Aubry, J., Nuermberger, E., Grosset, J. (2007). Promising Clinical Efficacy of Streptomycin-Rifampin Combination for Treatment of Buruli Ulcer (Mycobacterium ulcerans Disease). Antimicrob. Agents Chemother. 51: 4029-4035 [Abstract] [Full Text]  
  • Lefrancois, S., Robert, J., Chauffour, A., Ji, B., Jarlier, V. (2007). Curing Mycobacterium ulcerans Infection in Mice with a Combination of Rifampin-Streptomycin or Rifampin-Amikacin. Antimicrob. Agents Chemother. 51: 645-650 [Abstract] [Full Text]  
  • Ji, B., Lefrancois, S., Robert, J., Chauffour, A., Truffot, C., Jarlier, V. (2006). In Vitro and In Vivo Activities of Rifampin, Streptomycin, Amikacin, Moxifloxacin, R207910, Linezolid, and PA-824 against Mycobacterium ulcerans.. Antimicrob. Agents Chemother. 50: 1921-1926 [Abstract] [Full Text]  
  • Goto, M., Nakanaga, K., Aung, T., Hamada, T., Yamada, N., Nomoto, M., Kitajima, S., Ishii, N., Yonezawa, S., Saito, H. (2006). Nerve Damage in Mycobacterium ulcerans-Infected Mice: Probable Cause of Painlessness in Buruli Ulcer. Am. J. Pathol. 168: 805-811 [Abstract] [Full Text]  
  • Etuaful, S., Carbonnelle, B., Grosset, J., Lucas, S., Horsfield, C., Phillips, R., Evans, M., Ofori-Adjei, D., Klustse, E., Owusu-Boateng, J., Amedofu, G. K., Awuah, P., Ampadu, E., Amofah, G., Asiedu, K., Wansbrough-Jones, M. (2005). Efficacy of the Combination Rifampin-Streptomycin in Preventing Growth of Mycobacterium ulcerans in Early Lesions of Buruli Ulcer in Humans. Antimicrob. Agents Chemother. 49: 3182-3186 [Abstract] [Full Text]  
  • Okenu, D. M. N., Ofielu, L. O., Easley, K. A., Guarner, J., Spotts Whitney, E. A., Raghunathan, P. L., Stienstra, Y., Asamoa, K., van der Werf, T. S., van der Graaf, W. T. A., Tappero, J. W., Ashford, D. A., King, C. H. (2004). Immunoglobulin M Antibody Responses to Mycobacterium ulcerans Allow Discrimination between Cases of Active Buruli Ulcer Disease and Matched Family Controls in Areas Where the Disease Is Endemic. CVI 11: 387-391 [Abstract] [Full Text]  
  • Dega, H., Bentoucha, A., Robert, J., Jarlier, V., Grosset, J. (2002). Bactericidal Activity of Rifampin-Amikacin against Mycobacterium ulcerans in Mice. Antimicrob. Agents Chemother. 46: 3193-3196 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»